Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 117
- Registration Number
- NCT02432274
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇫🇷Centre Oscar Lambret Lille, Lille, Rhone, France
🇫🇷CHU de Toulouse - Hopital des Enfants, Toulouse, France
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
- Conditions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 219
- Registration Number
- NCT02268812
European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)
- Conditions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 109
- Registration Number
- NCT01991041
An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 62
- Registration Number
- NCT01945710
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧UCL Cancer Institute, London, United Kingdom
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 954
- Registration Number
- NCT01761266
- Locations
- 🇬🇧
Facility # 3, London, Greater London, United Kingdom
🇬🇧Facility # 2, London, Greater London, United Kingdom
🇰🇷Facility # 6, Seoul, Korea, Republic of
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 41
- Registration Number
- NCT01618136
- Locations
- 🇬🇧
King's College London Guy's Hospital Campus, London, United Kingdom
🇬🇧Newcastle Upon Tyne NHS Foundation Trust, Newcastle Upon Tyne And Wear, United Kingdom
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 41
- Registration Number
- NCT01546688
- Locations
- 🇩🇪
Asklepiosklinik Barmbek, Hamburg, Germany
🇩🇪Georg-August-Universiat Gottingen, Gottingen, Germany
🇩🇪Clinical Research Hamburg, Hamburg, Germany
A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel
- Conditions
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 59
- Registration Number
- NCT01531920
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 260
- Registration Number
- NCT01404169
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳Beijing Huilongguan Hospital, Beijing, Beijing, China
🇨🇳Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
A Confirmation Study of Eribulin in Combination With Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 76
- Registration Number
- NCT01323530